Albine Martin, Ph. D.
Dr. Albine Martin brings over 20 years of operating and product commercialization experience within 3 three public companies representing the biotechnology, diagnostics and life sciences sector. Currently she holds roles as Entrepreneur in Residence at Johns Hopkins University and Biohealth Innovation with the goal of translating research technologies to market. Dr Martin provides translational leadership to advance academic intellectual property and secure bridge funding via Maryland Innovation Funds and angel investors. She has served as COO of Precision Biologics, (a clinical stage oncology company with a Companion Diagnostic) where she formulated a virtual business model and negotiated agreements to advance towards Phase 2 clinical trials. She has served as a sector expert and member with Active Angels, and New Dominion Angels where she led diligence and syndicated investments. As Vice President at Compugen (CGEN), she built a consumable/data driven revenue model and managed strategic alliances to advance both diagnostic and therapeutic candidates. During her tenure at Life Technologies [LIFE] she was responsible for the global portfolio as Senior Business Director and managed Joint Ventures and expansion within the Asia-Pacific region. She has collaborated with FDA/CBER to develop compliance standards and commercialization strategies for ancillary products within the Cellular Therapy arena. She was also part of the team that led the BLA approval and commercialization of the HPV molecular diagnostic test commercialized by Digene Diagnostics. She is a member of the NSF commercial reviewer panels for SIR 1/2 funding and MIT Enterprise Forum, Washington DC Chapter. Dr. Martin holds a PhD from the University of Maryland and served as a Staff Fellow at the National Institutes of Health and holds a Certificate of Financial Management from Cornell University and is a graduate of the Program on Leadership and Strategy in Pharmaceuticals and Biotech at the Harvard Business School.